Mannitol

Generic Name: Mannitol

Brand Names: Aridol, Bronchitol, Cystosol, Osmitrol, Sag-M

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₄O_₆

CAS Number: 69-65-8

Unique Ingredient Identifier: 3OWL53L36A

Background: Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. Mannitol elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. As a result, cerebral edema, elevated i...

Indication: Used for the promotion of diuresis before irreversible renal failure becomes established, the reduction of intracranial pressure, the treatment of cerebral edema, and the promotion of urinary excretion of toxic substances.
...

Associated Conditions: Acute Renal Failure (ARF), Cystic Fibrosis (CF), Edema of the cerebrum, Increased Intra Ocular Pressure (IOP)

Associated Therapies: Bladder irrigation therapy

Clinical Trials

Acute Effects of Cortisol on Heroin Craving in Opioid Dependence (Ghost-Basel)

Phase 2

Completed

Conditions: Opioid Dependence

Interventions: Drug: Cortisol 20 mg
Drug: Mannitol

First Posted Date: 2012-11-01

Last Posted Date: 2013-10-30

Lead Sponsor: Prof. Dominique de Quervain, MD

Target Recruit Count: 30

Registration Number: NCT01718964

Locations: 🇨🇭
Psychiatric Hospital, Basel, Switzerland

Change in Airway Responsiveness After Allergen Exposure

Not Applicable

Completed

Conditions: Allergic Asthma

Interventions: Drug: Mannitol
Drug: Methacholine Chloride

First Posted Date: 2012-10-03

Last Posted Date: 2015-04-09

Lead Sponsor: University of Saskatchewan

Target Recruit Count: 11

Registration Number: NCT01699594

Locations: 🇨🇦
University of Saskatchewan, Saskatoon, Saskatchewan, Canada

Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes

Phase 3

Completed

Conditions: Renal Cancer

Interventions: Other: placebo
Drug: mannitol

First Posted Date: 2012-05-28

Last Posted Date: 2018-10-15

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 210

Registration Number: NCT01606787

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and Placebo

Phase 2

Conditions: Cystic Fibrosis
Pneumonia

Interventions: Drug: Mannite
Drug: Amitriptyline

First Posted Date: 2011-03-07

Last Posted Date: 2011-03-07

Lead Sponsor: University Children's Hospital Tuebingen

Target Recruit Count: 30

Registration Number: NCT01309178

Locations: 🇩🇪
Lutz Naehrlich, Giessen, Germany
🇩🇪
Joachim Riethmueller, Tuebingen, Germany
🇩🇪
Jochen Mainz, Jena, Germany

Boron Phenylalanine With or Without Mannitol in Treating Patients With Glioblastoma Multiforme

Phase 1

Terminated

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2010-11-03

Last Posted Date: 2013-10-08

Lead Sponsor: Cancer Research UK

Target Recruit Count: 36

Registration Number: NCT01233492

Locations: 🇬🇧
Cancer Research UK Clinical Trials Unit - Birmingham, Birmingham, England, United Kingdom
🇬🇧
Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham, England, United Kingdom

Osmotic Therapy for Treatment of Intracranial Hypertension for Traumatic Brain Injury

Not Applicable

Withdrawn

Conditions: Traumatic Brain Injury

Interventions: Drug: NaCl
Drug: Mannitol

First Posted Date: 2010-10-05

Last Posted Date: 2013-04-04

Lead Sponsor: Indiana University

Registration Number: NCT01215019

Locations: 🇺🇸
Wishard Memorial Hospital, Indianapolis, Indiana, United States

Wheeze and Intermittent Treatment

Phase 3

Completed

Conditions: Wheezing

Interventions: Drug: Mannitol
Drug: Montelukast

First Posted Date: 2010-06-11

Last Posted Date: 2014-04-29

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 1358

Registration Number: NCT01142505

Locations: 🇬🇧
Barts and the London NHS Trust, London, United Kingdom

Hypertonic Saline vs. Mannitol for Elevated Intercranial Pressure

Phase 3

Terminated

Conditions: Traumatic Brain Injury
Elevated Intracranial Pressure

Interventions: Drug: Mannitol
Drug: Hypertonic Saline

First Posted Date: 2010-04-27

Last Posted Date: 2013-03-05

Lead Sponsor: University of Cincinnati

Target Recruit Count: 5

Registration Number: NCT01111682

Locations: 🇺🇸
University Hospital, Cincinnati, Ohio, United States

Double Blind Study of Hypertonic Saline vs Mannitol in the Management of Increased Intracranial Pressure (ICP).

Not Applicable

Withdrawn

Conditions: Elevated Intracranial Pressure

Interventions: Drug: hypertonic saline
Drug: Mannitol

First Posted Date: 2010-04-22

Last Posted Date: 2017-03-16

Lead Sponsor: Beth Israel Deaconess Medical Center

Registration Number: NCT01108744

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

High Dose Inhaled Mannitol Study

Phase 1

Completed

Conditions: Bronchiectasis

First Posted Date: 2010-02-26

Last Posted Date: 2010-02-26

Lead Sponsor: Syntara

Target Recruit Count: 10

Registration Number: NCT01076491

Locations: 🇦🇺
Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy